The Dosimetry Core has been established at CMMI for about 6 years. The purpose of this core was todevelop standard procedures for processing pharmacokinetic and dosimetry data for CMMI-sponsoredclinical trials, but this core also assists investigators at CMMI in preclinical evaluation. The core isresponsible for first training sites in the methodology that CMMI requires of its imaging protocols andensures all equipment, both internally and at extramural sites, are properly calibrated and maintained. Thecore receives digital and hard copies of all imaging studies performed by investigational sites for CMMIclinical protocols. The core will then reviews these images and prepares regions of interest from whichtime-activity curves can be generated. A trained nuclear physician and a nuclear medicine technologistsupervise this work. As an additional quality assurance check, CMMI also has these data reviewed by aqualified radiation health physicist (for this Program Project, Dr. Jeff Siegel). This core also isresponsible for processing pharmacokinetic data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA103985-04
Application #
7728854
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-08-01
Project End
2009-07-31
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
4
Fiscal Year
2008
Total Cost
$52,739
Indirect Cost
Name
Center for Molecular Medicine/Immunology
Department
Type
DUNS #
118870583
City
Morris Plains
State
NJ
Country
United States
Zip Code
07950
Smith, Mitchell R; Jin, Fang; Joshi, Indira (2014) Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-?B dependent human transformed follicular lymphoma cell line. Br J Haematol 165:151-3
Binsky-Ehrenreich, I; Marom, A; Sobotta, M C et al. (2014) CD84 is a survival receptor for CLL cells. Oncogene 33:1006-16
Chen, X; Chang, C-H; Stein, R et al. (2012) The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD. Bone Marrow Transplant 47:967-80
Sharkey, Robert M; Goldenberg, David M (2011) Cancer radioimmunotherapy. Immunotherapy 3:349-70
Stein, Rhona; Balkman, Cheryl; Chen, Susan et al. (2011) Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma. Leuk Lymphoma 52:273-84
Rossi, Edmund A; Rossi, Diane L; Cardillo, Thomas M et al. (2011) Preclinical studies on targeted delivery of multiple IFN?2b to HLA-DR in diverse hematologic cancers. Blood 118:1877-84
Alinari, Lapo; Yu, Bo; Christian, Beth A et al. (2011) Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood 117:4530-41
Brem, Elizabeth A; Thudium, Karen; Khubchandani, Sapna et al. (2011) Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. Br J Haematol 153:599-611
Olejniczak, Scott H; Blickwedehl, Jennifer; Belicha-Villanueva, Alan et al. (2010) Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells. Blood 116:5605-14
Gupta, Pankaj; Goldenberg, David M; Rossi, Edmund A et al. (2010) Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. Blood 116:3258-67

Showing the most recent 10 out of 43 publications